LSIPR 50 2017: Beth Seidenberg
Name: Beth Seidenberg
Organisation: Kleiner Perkins Caufield & Byers
Position: General partner
Working with entrepreneurs to develop companies with breakthrough technology for treating patients and improving the delivery of healthcare, Beth Seidenberg was ranked number 98 in the 2016 Forbes ‘Midas List’.
"She is becoming an advocate for women in life sciences and investment."
Seidenberg is a general partner at Kleiner Perkins Caufield & Byers (KPCB), where she focuses on life sciences and investing in digital health and biotech companies.
She has led investments in Flexius Biosciences, a cancer immunotherapy company, Ipierian, a neurological biotech company, and Practice Fusion, a web-based health record firm.
Along with Seidenberg’s work on life sciences investments, before joining KPCB in 2005 she held executive roles at Amgen, Bristol-Myers Squibb and Merck.
Having a senior influence in the biotech industry, Seidenberg does more than develop companies: she is becoming an advocate for women in life sciences and investment and has previously voiced her opinion on the subject of women in the life sciences industry.
Seidenberg grew up in New York and received her BS degree from Barnard College and her MD from the University of Miami.
She completed her postgraduate training at John Hopkins University, George Washington University and the National Institutes of Health.
